Compare Danaher Corporation (DHR) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs L3Harris Technologies Inc — how do they compare? Danaher Corporation trades at $200.83 (market cap $140.88B), while L3Harris Technologies Inc trades at $289.26 (market cap $54.03B). The key difference: Danaher Corporation is far larger — about 2.6× L3Harris Technologies Inc's market cap, and L3Harris Technologies Inc pays the higher dividend (1.72%). Which is the better fit depends on your goals.
| DHR | LHX | |
|---|---|---|
Market Cap | $140.88B | $54.03B |
Sector | Health | Industrials |
52-Week High | $242.05 | $378.48 |
52-Week Low | $161.91 | $261.17 |
Enterprise Value | $153.66B | $64.79B |
Dividend Yield | 0.8% | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
LHX trades at $288.69, down 0.72% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $2.72, beating estimates of $2.53, continuing a trend of earnings beats. Revenue grew to $21.87 billion in 2025, with net income margin improving to 7.34%. Recent contract wins include a U.S. Space Force satellite deal and U.S. Army communications orders, supporting growth prospects.
The outlook remains positive with a consensus price target of $367.50, implying 27% upside, and 75% of analysts rate it a Buy. Risks include execution on record $40.7 billion backlog, debt levels, and defense budget volatility. The stock offers dividend income with a $1.25 quarterly payout, balancing growth and income appeal for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
